Research funder · United States
Children's Tumor Foundation
Foundation dedicated to improving the health and well-being of individuals and families affected by neurofibromatosis
- Grants since 2016
- 436
- Awarded, last 5 years (where amounts are published)
- 28.1M
- Funded works, last 5 years
- 115
- Funded works, all time
- 426
Grants
2025–2027 · award
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)
Lorenzo Trippa · Dana-Farber Cancer Institute
2025–2027 · award
A stem cell basis for NF1-associated skeletal manifestations
Federico La Manna · Cornell University
2025–2027 · award
Utilizing protein scavenging for the treatment of NF1-deficient MPNST
Craig Ramirez · Tezcat Biosciences, Inc.
2025–2027 · award
Harnessing Engineered Bacterial Outer membrane Vesicles to Turn Cold NF2-Schwannomas Hot for Enhanced Immunotherapy.
Sherif Ahmed · Massachusetts General Hospital
2025–2027 · award
Advancing Precision Medicine for Adolescents and Young Adults with Neurofibromatosis Type 2 and Meningiomas Through Multi-Omics and Artificial Intelligence
Leo Yefet · University Health Network
2025–2027 · award
Targeting RAS for schwannoma therapy
Anna Sablina · Vlaams Instituut voor Biotechnologie
2025–2027 · award
In vitro and in vivo validation of clinically relevant drugs and new compounds for the treatment of MPNSTs
Piotr Topilko · Paris-Est Sup
2025–2027 · award
Genomics-assisted early detection, diagnosis and management of NF1-related tumors
Miriam Magallon · Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2025–2027 · award
Analyzing the role and therapeutic potential of ALDH1A3 in NF2-null meningioma
Libby Williams · University of Plymouth
2025–2032 · award
TBD
Michael Fisher · Children's Hospital of Philadelphia
2025–2027 · award
Validation of Metabotropic Glutamate Receptor 7 as a Potential Genetic Modifier and Therapeutic Treatment for Cognitive Symptoms in Neurofibromatosis Type I
Colleen Niswender · Vanderbilt University
2025–2027 · award
Gene therapy to prevent NF2-associated vestibular schwannomas
Alexandra O'Donohue · Sydney Children’s Hospitals Network
2025–2028 · award
Neurofibromatosis Open Science Initiative (NF-OSI)- MDA and Addendum 12
Robert Allaway · Sage Bionetworks
2024–2026 · award
Investigating the role of ZNF423 in NF1-related MPNST
Sarah Morrow · Indiana University
2024–2026 · award
Evaluating the role of T cells in NF1-peripheral nerve sheath tumor (PNST) progression
Emily White · Indiana University
2024–2026 · award
GsMTtx-4 as a novel inhibitor to block non-NF2 SWN pain
Kimberly Ostrow · Johns Hopkins University
2024–2026 · award
Targeting HIF-2 for the treatment of NF2 Vestibular Schwannoma
Lei Xu · Massachusetts General Hospital
2024–2026 · award
Pathways that drive inflammation and EMT in Schwann cells after NF1 loss
Ramya Ravindran · Children's Hospital Medical Center
2024–2026 · award
Targeting PRMT5 in MTAP-deleted NF1 High Grade Gliomas
Ljubica Caldovic · Children's Research Institute (cnmc)
2024–2026 · award
Evaluation of a Novel Physiologic Biomarker of Pain in Neurofibromatosis Type 1
Pamela Wolters · National Cancer Institute
2024–2025 · award
CTF-Taconic-Cyagen NF1 and NF2 mouse model validation
D. Wade Clapp · Indiana University
2024–2027 · award
Developing a humanised meningioma mouse model for NF2-related schwannomatosis (R)
Liyam Laraba · University of Plymouth
2024–2025 · award
Assessing efficacy of L-carnitine supplementation to treat muscle fatigue and weakness in children with NF1. A placebo controlled, blinded clinical trial.
Yemima Berman · Northern Sydney Local Health District
2024–2026 · award
Repurposing Montelukast to treat plexiform neurofibromas in combination with Selumetinib
Daochun Sun · Medical College of Wisconsin
2024–2026 · award
Evaluation of a Novel Physiologic Biomarker of Pain in Neurofibromatosis Type 1 - NCI/CNH collaboration
Julia Finkel · Children's National
2024–2026 · award
Exploring the Interplay between Lipid Metabolism and LZTR1 in Peripheral Nerve Pathologies
Georgia Daraki · Leibniz Institute on Aging - Fritz Lipmann Institute (FLI)
2024–2026 · award
Deciphering crucial cell death pathways in NF2-related schwannomatosis
Anna Nagel · University of Central Florida
2024–2026 · award
Identification of Biomarkers in Children and Adults with NF1 associated Plexiform Neurofibromas Treated with Binimetinib; an NF 108 Exploratory Aim
Stephen Gilene · Cincinnati Children's Hospital Medical Center
2024–2026 · award
Trancriptional regulation of tumor stem cells in neurofibroma development
Stefanie Moye · The University Of Texas Southwestern Medical Center (ut Southwestern)
2024–2027 · award
Development of a novel zebrafish model for NF1-related learning and cognitive deficits
Ljubica Caldovic · Children's Research Institute (cnmc)
2024–2026 · award
Developmental Analyses of Skeletal Manifestations in “Mild” Neurofibromatosis Type I Patient Mutation p.M992del in Knock-In Mouse Model
Alexis Stillwell · Board Of Supervisors Of Louisiana State University Agricultural And Mechanical College Represented By Pennington Biomedical Research Center
2024–2026 · award
Temporal Trends in Plasma Biomarkers: Implications for Hearing and Tumor Progression in People with Vestibular Schwannoma
Konstantina Stankovic · Stanford Medicine
2024–2026 · award
Proteome analysis of inner ear fluids in NF2 mouse models with hearing loss
Isam Naber · Stanford University
2024–2025 · award
Validate the tamoxifen-inducible Postn-CreERT2-T2A-FLPo transgenic mouse
Simon J. Conway · Indiana University
2024–2026 · award
Genetic and molecular investigation of the neuronal functions of NF1.
Alex Dyson · Massachusetts General Hospital
2024–2026 · award
In vivo assessment of BET blockade combined with PARP inhibition to sensitize MPNST to radiation therapy
Keila Torres · The University of Texas MD Anderson Cancer Center
2024–2026 · award
Identification and Functional Validations of Actionable Targets for Prevention or Treatment of Cutaneous Neurofibromas and Characterization of NF1 Healthy-Looking Skin
Pernelle Pulh · Paris-Est Sup
2024–2026 · award
Identifying Moyamoya: MRI and TCD in Children with Neurofibromatosis Type I (MATCh) Study
Laura Lehman · Boston Children's Hospital
2023–2024 · award
Identification of drugs targeting epigenetic regulators in an iPSC-based 3D MPNST model
Eduard Serra-Arenas · Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2023–2024 · award
Developing a thrombopoietin inhibitor to treat NF2 hearing loss and schwannoma growth
Lawrence Sherman · Oregon Health & Science University